Philadelphia, PA, December 4, 2013 – Depression is a serious mental illness that has many negative consequences for sufferers. But depression among pregnant women may also have an impact on their developing babies.
Children of depressed parents are at an increased risk of developing depression themselves, a combination of both genetic and environmental factors. These children also display alterations in the amygdala, a brain structure important for the regulation of emotion and stress. However, prior work in this area has assessed children years after birth, which means that the timing of these alterations has remained unidentified.
Researchers led by Dr. Anqi Qiu at the National University of Singapore now have the answers, with their new work published in the current issue of Biological Psychiatry.
They set out to perform a direct analysis of prenatal maternal depression and variation in the fetal development of the amygdala. To do so, they recruited 157 pregnant women who completed a depression questionnaire during their 26th week of pregnancy. Later, within two weeks of birth, newborns underwent magnetic resonance imaging scans to ascertain the structure of their amygdala and diffusion tensor imaging scans to determine the integrity of the amygdala's pattern of neural connections.
The volume of the amygdala did not differ between the infants regardless of their mothers' depression status. However, the researchers found significantly reduced structural connectivity (i.e., lower fractional anisotropy and lower axial diffusivity) in the right amygdala of infants of mothers with high levels of depression symptoms. In other words, the amygdala's microstructure (e.g., its "wiring") was abnormal in the infants born to depressed mothers.
This important finding suggests that a propensity for abnormal amygdala function, a feature of mood and anxiety disorders, may be transmitted from mother to child during fetal life. This finding suggests one new path that a history of maternal depression might contribute to a life-long increase in the vulnerability to mental illness.
This study provides added evidence supporting the notion that mental health screening should be included among the medical evaluations that women undergo when they discover that they are pregnant. Indeed, the authors conclude that their study supports that "interventions targeting maternal depression should begin early in pregnancy."
"Attention to maternal health during pregnancy is an extremely high priority for society for many reasons," added Dr. John Krystal, Editor of Biological Psychiatry. "The notion that maternal depression might influence the brain development of their babies is very concerning. The good news is that this risk might be reduced by systematic screening of pregnant women for depression and initiating effective treatment."
The article is "Prenatal Maternal Depression Associates with Microstructure of Right Amygdala in Neonates at Birth" by Anne Rifkin-Graboi, Jordan Bai, Helen Chen, Waseem Bak'r Hameed, Lit Wee Sim, Mya Thway Tint, Birit Leutscher-Broekman, Yap-Seng Chong, Peter D. Gluckman, Marielle V. Fortier, Michael J. Meaney, and Anqi Qiu (doi: 10.1016/j.biopsych.2013.06.019). The article appears in Biological Psychiatry, Volume 74, Issue 11 (December 1, 2013), published by Elsevier.
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Dr. Anqi Qiu at email@example.com.
The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 4th out of 135 Psychiatry titles and 13th out of 251 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2012 Impact Factor score for Biological Psychiatry is 9.247.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, MD Consult and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+1 214 648 0880
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.